1 Department of Medical Oncology, Inselspital, University Hospital Bern; University of Bern; Bern, Switzerland.
2 Department of Hematology and Central Hematology Laboratory, Inselspital, University Hospital Bern; University of Bern; Bern, Switzerland.
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
CAR-T cell therapy is likely to be introduced starting from 2021 in
patients with relapsed/refractory myeloma (r/r MM) in Europe. In order
to qualify for commercial CAR-T treatment, it is assumed that r/r MM
patients will have to be exposed to at least three lines of previous
treatments including lenalidomide, bortezomib and anti-CD38 treatment.
However, the outcome of this particular subgroup of r/r MM patients is
largely unknown whereas this knowledge is crucial to estimate the
possible benefit of eventual CAR-T treatment.
1. Patient characteristics at first diagnosis of the multiple myeloma.
|Table 2. Treatments prior and including first daratumumab treatment.
|Table 3. Treatments after first daratumumab treatment.
1. Kaplan-Meyer curves depicting (A) progression free survival, (B)
time to next treatment and (C) overall survival of myeloma patients for
the first subsequent treatment line after inclusion in the study, thus,
after at least three previous treatment lines.